More than 10,000 doses of illegally imported retatrutide, a potent experimental weight-loss drug often referred to as the “Godzilla” fat jab, have been seized at the United Kingdom’s borders in the first nine months of 2026. This represents a significant increase compared to just six doses intercepted throughout the entirety of 2025, highlighting a surge in the smuggling and distribution of unlicensed fat-busting injections.
Retatrutide is currently under late-stage clinical trials by pharmaceutical company Eli Lilly and is not approved for human use anywhere globally. The drug has shown promising results in trials, with some participants experiencing nearly 30 percent reductions in body weight. Despite its ongoing status, counterfeit versions have appeared on the UK black market and are being promoted openly via social media platforms including TikTok, Instagram, Facebook, and WhatsApp.
Investigations reveal that retatrutide now accounts for approximately 93 percent of all seized illicit weight-loss injection doses at UK entry points. Overall border seizures of counterfeit and unlicensed weight-loss jabs have escalated dramatically, rising from 435 doses in 2025 to over 11,200 doses so far this year. Law enforcement operations have also uncovered clandestine production facilities manufacturing these fake injections, resulting in the confiscation of nearly 69,000 additional doses since early last year.
Laboratory analyses conducted on 72 suspect samples collected since the start of 2025 found that 17 contained no identifiable weight-loss drug, indicating that some users may be injecting unknown and potentially dangerous substances. Other samples showed wide variability in retatrutide concentrations, with doses ranging from 6 mg to 25 mg per milliliter, leaving consumers unaware of the amount they are administering to themselves.
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a warning urging individuals to exercise extreme caution when purchasing medicines online, emphasizing the risks associated with unregulated products. The agency highlighted the potential dangers of self-administering unlicensed medical treatments sourced from unauthorized suppliers.
The rapid increase in the smuggling and illicit sale of retatrutide underscores the challenges regulators and law enforcement face in controlling the distribution of experimental and counterfeit pharmaceuticals. Authorities continue to monitor and intervene in these illegal supply networks as concerns grow over public health implications.